These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21396199)

  • 1. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review.
    Monedero I; Caminero JA
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):433-9. PubMed ID: 21396199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
    Blomberg B; Spinaci S; Fourie B; Laing R
    Bull World Health Organ; 2001; 79(1):61-8. PubMed ID: 11217670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
    Catalani E
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.
    Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?
    Suryanto AA; van den Broek J; Hatta M; de Soldenhoff R; van der Werf MJ
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):174-9. PubMed ID: 18230250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?
    Blomberg B; Kitler ME; Milstien J; Dellepiane N; Fanning A; Norval PY; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S371-80; discussion S381-7. PubMed ID: 10593721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
    Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.
    Blomberg B; Fourie B
    Drugs; 2003; 63(6):535-53. PubMed ID: 12656652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography.
    Kenyon TA; Kenyon AS; Kgarebe BV; Mothibedi D; Binkin NJ; Layloff TP
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S347-50; discussion S351-2. PubMed ID: 10593716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug resistance in tuberculosis].
    Winje BA; Mannsåker T; Langeland N; Heldal E
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2588-92. PubMed ID: 19023372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective.
    Panchagnula R; Agrawal S; Ashokraj Y; Varma M; Sateesh K; Bhardwaj V; Bedi S; Gulati I; Parmar J; Kaul CL; Blomberg B; Fourie B; Roscigno G; Wire R; Laing R; Evans P; Moore T
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):703-21. PubMed ID: 15632956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research and control of relapse tuberculosis cases].
    Yamagishi F; Toyota M
    Kekkaku; 2009 Dec; 84(12):767-8. PubMed ID: 20077861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements for anti-tuberculosis drug tender requests.
    Trébucq A; Caudron JM; Pinel J
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S358-61; discussion S381-7. PubMed ID: 10593718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.